You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm's overall growth in the quarter was led largely by 9 percent growth in its Diagnostics and Genomics Group.
The company also said it launched a new comprehensive diagnostic called HeartCare for surveillance of heart transplant patients.
The decline was in line with what the company preliminarily reported last month, reflecting much lower collaboration revenues than in the prior year period.
The firm placed 65 sample-to-answer systems under contract in the second quarter compared to 35 systems in the prior-year quarter.
The company's life sciences segment had $1.08 billion in revenues, driven by strong performance of the preanalytical systems, diagnostic systems, and biosciences units.
The company said volumes for its Cologuard colon cancer screening test rose 59 percent to 215,000 during the quarter.
The firm's diagnostics division was up 4 percent. Molecular diagnostics grew 7 percent, cytology & perinatal was flat, and blood screening was down 2 percent.
Revenues for Roche Diagnostics totaled CHF 6.26 billion for H1, driven primarily by demand for immunodiagnostic solutions.
The company's revenues totaled $6.08 billion, up from $4.99 billion during Q2 of 2017.
The firm said that its average revenue per clinical genetic test decreased by almost 4 percent to $318, primarily due to changes in Medicare reimbursement and regulation.
Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.
Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.
The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.
In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.